
Acrivon Therapeutics, Inc. Common Stock
- Jurisdiction
United States - ISIN
US0048901096 (ACRV )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. Read full profile
Stock price
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€81.00M - EBIT margin
0.0% - Net income
-€73.75M - Net margin
0.0%
Statement period: - (published )
Dividends
No dividend payouts
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Buy |